MHRA (UK) approves Yselty to treat symptoms of uterine fibroids.- ObsEva SA.
ObsEva SA announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.
Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF. The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
Related news and insights
Genmab A/S announced the FDA granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy
Actinium Pharmaceuticals, Inc reported new analyses from the positive Phase III SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research)
Genentech, a member of the Roche Group, announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting